Cipla

From Wikipedia, the free encyclopedia

Cipla Limited
TypePublic
BSE: 500087
NSE: CIPLA
NSE NIFTY 50 Constituent
ISININE059A01026
IndustryPharmaceuticals
Founded1935 (86 years ago) (1935)
FounderKhwaja Abdul Hamied
HeadquartersMumbai, Maharashtra, India
Area served
Worldwide
Key people
Y. K. Hamied (Chairman)
Umang Vohra (CEO)
ProductsPharmaceuticals and diagnostics
RevenueIncrease ₹17,476.19 crore (US$2.5 billion) [1] (2020)
Increase ₹3,205.99 crore (US$450 million) [2] (2020)
Increase ₹1,546.98 crore (US$220 million) [1] (2020)
Total assetsDecrease ₹23,662.56 crore (US$3.3 billion) [3] (2020)
Total equityIncrease ₹15,763.00 crore (US$2.2 billion) [3] (2020)
Number of employees
22,036[4]
SubsidiariesInvagen Pharmaceuticals
Websitewww.cipla.com

Cipla Limited is an Indian multinational pharmaceutical company, headquartered in Mumbai, India. Cipla primarily develops medicines to treat respiratory, cardiovascular disease, arthritis, diabetes, weight control and depression; other medical conditions.[5]

As of 17 September 2014, its market capitalisation was ₹49,611.58 crore (equivalent to ₹530 billion or US$7.5 billion in 2019), making it India's 42nd largest publicly traded company by market value.[6][7][8]

On 23 April 2019, Cipla appointed Dr. Raju Mistry as Global Chief People Officer.[9]

History[]

It was founded by Khwaja Abdul Hamied as 'The Chemical, Industrial & Pharmaceutical Laboratories' in 1935 in Mumbai.[10][11] The name of the company was changed to 'Cipla Limited' on 20 July 1984.[11] In the year 1985, the US FDA approved the company's bulk drug manufacturing facilities.[12] Led by the founder's son Yusuf Hamied, a Cambridge-educated chemist, the company provided generic AIDS and other drugs to treat poor people in the developing world.[13] In 1995, Cipla launched Deferiprone, the world's first oral iron chelator.[10] In 2001, Cipla offered medicines (antiretrovirals) for HIV treatment at a fractional cost (less than $350 per year per patient).[14]

In 2013 Cipla acquired the South African company Cipla-Medpro, kept it as a subsidiary, and changed its name to Cipla Medpro South Africa Limited.[15][16] At the time of the acquisition Cipla-Medpro had been a distribution partner for Cipla and was South Africa's third biggest pharmaceutical company.[15] The company had been founded in 2002 and was known as Enaleni Pharmaceuticals Ltd.[17] In 2005, Enaleni bought all the shares of Cipla-Medpro, which had been a joint venture between Cipla and Medpro Pharmaceuticals, a South African generics company,[18] and in 2008 it changed its name to Cipla-Medpro.[19]

Products and services[]

Cipla sells active pharmaceutical ingredients to other manufacturers as well as pharmaceutical and personal care products,[20] including Escitalopram (anti-depressant), Lamivudine and Fluticasone propionate.[4] They are the world's largest manufacturer of antiretroviral drugs[20][21]

In July 2020, the company announced the introduction of Gilead Sciences' Remdesivir under the brand name CIPREMI in India after reaching a voluntary licensing agreement with parent company[22] and DCGI approval for "restricted emergency use" in COVID-19 treatment of critical confirmed patients.[23][24]

Operations[]

Cipla has 34 manufacturing units in 8 locations across India and a presence in over 80 countries.[25][26] Exports accounted for 48% ₹4,948 crore (equivalent to ₹68 billion or US$950 million in 2019) of its revenue for FY 2013–14.[27] Cipla spent INR 517 cr. (5.4% of revenue) in FY 2013–14 on R&D activities.[27] The primary focus areas for R&D were development of new formulations, drug-delivery systems and APIs (active pharmaceutical ingredients). Cipla also cooperates with other enterprises in areas such as consulting, commissioning, engineering, project appraisal, quality control, know-how transfer, support, and plant supply.

As on 31 March 2013, the company had 22,036 employees (out of which 2,455 were women (7.30%) and 23 were employees with disabilities (0.1%)).[4] During the FY 2013–14, the company incurred ₹1,285 crore (equivalent to ₹17 billion or US$230 million in 2019) on employee benefit expenses.[27]

Listings and shareholding[]

The equity shares of Cipla are listed on the Bombay Stock Exchange,[28] where it is a constituent of the BSE SENSEX index,[29] and the National Stock Exchange of India,[30] where it is a constituent of the CNX Nifty.[31] Its Global Depository Receipts (GDRs) are listed on the Luxembourg Stock Exchange.[27]

As of 30 September 2014, the promoter group, Y. K. Hamied and his family held around 36.80% equity shares in Cipla. Around 148,000 individual shareholders held approx. 18.67% of its shares.[32] LIC is the largest non-promoter shareholder with approx. 6.45% shareholding in the company by the end of September 2013.[33]

Shareholders (as on 31-March-2014) Shareholding[32]
Promoter Group 36.80%
Foreign Institutional Investors (FII) 23.32%
Individual shareholders 19.00%
Insurance companies 10.30
Private Corporate Bodies 04.68%
Mutual Funds and UTI 04.43%
NRI/FCB/Others 03.46%
GDRs 01.10%
Total 100.0%

Awards and recognitions[]

  • In 2012, Cipla received the Thomson Reuters India Innovation Award.[34]
  • Cipla won Dun & Bradstreet American Express Corporate Awards in 2006.[35]
  • In 2007, Forbes included Cipla in the 200 'Best under a billion' list of best small Asian companies.[36]
  • In 1980, Cipla won Chemexcil Award for Excellence for exports.[12]
  • In 2015, Cipla stood third in the (Pharmaceutical) list,[37] in a study conducted by BlueBytes,[38] a leading Media Analytics firm in association with TRA Research,[39] a brand insights organization (both a part of the Comniscient Group).

Criticism[]

Emergency contraception[]

In August 2007, Cipla launched an emergency contraception drug "i-pill" sold over the counter,[40] which was controversial with regard to its being available without a prescription and the large amount of drug contained per dose.[41][42]

Generic drugs[]

In the late 1960s, Cipla began manufacturing a new, patented drug, propranolol, without the permission of the drug's patent holder, Imperial Chemical Industries (ICI), which protested to the Indian government. The CEO of Cipla reached the government of Indira Gandhi to change India's patent laws to eliminate patents that directly covered drugs, and instead to allow only patents that covered methods to make drugs.[43] so that Cipla could go ahead and produce as many low-priced generic drugs for the poor as possible. Since then Cipla has also produced a low-cost drug to treat HIV and expanded operations into several developing countries, including African nations, where most HIV and poor patients existed at one time.[44] But the changes made led to criticism of both India's patent laws and Cipla.[45] India reinstated patents on drugs in 2005.[43]

See also[]

References[]

  1. ^ Jump up to: a b "Cipla Consolidated Profit & Loss account, Cipla Financial Statement & Accounts". www.moneycontrol.com. Retrieved 28 July 2020.
  2. ^ "Cipla Consolidated Profit & Loss account, Cipla Financial Statement & Accounts". www.moneycontrol.com. Retrieved 21 June 2020.
  3. ^ Jump up to: a b "Cipla Consolidated Balance Sheet, Cipla Financial Statement & Accounts". www.moneycontrol.com. Retrieved 28 July 2020.
  4. ^ Jump up to: a b c "Business Responsibility Report 2013-14" (PDF). Cipla. 15 July 2014. Archived from the original (PDF) on 17 March 2015. Retrieved 17 September 2014.
  5. ^ "How a little blue pill changed Cipla's fortunes".
  6. ^ "Top Companies by Market Capitalisation". Money Control. 17 September 2014. Retrieved 17 September 2014.
  7. ^ Cipla to sell MSD’s HIV drug in India | Business Line
  8. ^ Cipla, Hetero to roll out biosimilar drug | Business Line
  9. ^ "Cipla appoints Dr Raju Mistry as Global Chief People Officer". Medical Dialogues. 23 April 2019. Retrieved 23 April 2019.
  10. ^ Jump up to: a b "About us - History". Cipla Limited. Archived from the original on 27 October 2015. Retrieved 3 November 2014.
  11. ^ Jump up to: a b "Company History - Cipla Ltd". Economic Times. Retrieved 3 November 2013.
  12. ^ Jump up to: a b "Company Profile - Cipla Limited". IndiaInfoline.com. Retrieved 3 November 2013.
  13. ^ "Interview with Yusuf Hamied". Creating Emerging Markets. Harvard Business School.
  14. ^ "Indian drug company offers cheap AIDS drugs". USA Today. 19 June 2001. Retrieved 3 November 2013.
  15. ^ Jump up to: a b Jawani, Lohit (16 July 2013). "Cipla completes acquisition of South Africa's Cipla Medpro". VC Circle. Archived from the original on 15 March 2016. Retrieved 8 September 2016.
  16. ^ "Delists from JSE". Business Day Live. 2013. Retrieved 13 July 2013.
  17. ^ "Enaleni Pharmaceuticals Limited Prospectus 2005". Morningstar. Retrieved 8 September 2016.
  18. ^ Avafia, Tenu; Berger, Jonathan; Hartzenberg, Trudi (2006). "The ability of select sub-Saharan African countries to utilise TRIPs Flexibilities and Competition Law to ensure a sustainable supply of essential medicines: A study of producing and importing countries" (PDF). WHO.
  19. ^ Kahn, Tamar (10 September 2008). "South Africa: Enaleni Takes Name of Its Unit Cipla-Medpro". All Africa.
  20. ^ Jump up to: a b "cipla ltd (CIPLA:Natl India)". Business Week. Archived from the original on 6 November 2013. Retrieved 7 November 2013.
  21. ^ "AIDS Healthcare Foundation Campaign Challenges Cipla Over Drug Pricing in India". PR Newswire. 8 August 2007. Retrieved 4 November 2013.
  22. ^ "India gives Hetero Labs and Cipla approval to make Gilead's COVID-19 drug". Reuters. 21 June 2020.
  23. ^ "Coronavirus drug: Cipla launches Cipremi's, claims it is the cheapest Remdesivir". The Financial Express. 9 July 2020.
  24. ^ "Coronavirus drug: Cipla ramps up production of antiviral remdesivir amid demand spurt". www.businesstoday.in.
  25. ^ "Corporate Information: At a Glance". Cipla. Archived from the original on 12 September 2016. Retrieved 6 July 2019.
  26. ^ "Cipla in the pink of health". Business Standard. 25 September 2013. Retrieved 5 November 2013.
  27. ^ Jump up to: a b c d "Annual Report 2013-14" (PDF). Cipla. 22 August 2014. Archived from the original (PDF) on 22 January 2015. Retrieved 17 September 2014.
  28. ^ "Cipla Limited". BSEindia.com. Retrieved 2 November 2013.
  29. ^ "Scripwise Weightages in S&P BSE SENSEX". BSE India. Archived from the original on 1 December 2015. Retrieved 2 November 2013.
  30. ^ "NTPC Limited". NSE India. Retrieved 2 November 2013.
  31. ^ "Download List of CNX Nifty stocks (.csv)". NSE India. Retrieved 2 November 2013.
  32. ^ Jump up to: a b "Shareholding pattern as on 30th September, 2013" (PDF). Cipla Limited. Archived from the original (PDF) on 2 November 2013. Retrieved 2 November 2013.
  33. ^ "CIPLA - Shareholding belonging to the category : "Public and holding more than 1% of the Total No.of Shares"". MoneyControl.com. 30 September 2013. Retrieved 4 November 2013.
  34. ^ DBT, Cipla get Thomson Reuters India innovation awards
  35. ^ "Pharmaceutical sector award". Dun & Bradstreet. 10 September 2006. Archived from the original on 4 November 2013. Retrieved 3 November 2013.
  36. ^ "Asian Paints, Cipla in Forbes list". Economic Times. 17 November 2005. Retrieved 3 November 2013.
  37. ^ "Lupin, Sun Pharma and Cipla amongst tops most reputed pharma brand list". The Economic Times. timesofindia.com. 17 August 2016. Retrieved 6 July 2019.
  38. ^ http://www.bluebytes.info
  39. ^ http://www.trustadvisory.info
  40. ^ "Cipla rises on morning-after pill". Hindustan Times. 5 October 2007. Archived from the original on 5 February 2015. Retrieved 3 November 2013.
  41. ^ "Cipla Launches i-pill". Financial Express. Retrieved 3 November 2013.
  42. ^ "'i-pill' by Cipla draws criticism from experts". Financial Express. 27 October 2007. Retrieved 3 November 2013.
  43. ^ Jump up to: a b "The Treasure of Mumbai". Wired Magazine. December 2006. Retrieved 4 November 2013.
  44. ^ "Heart-warming story of the Hamieds, who set up CIPLA and have been saving lives". National Herald. April 2020. Retrieved 12 April 2020.
  45. ^ "Indian Generic Drug Maker Targets Sad Americans". biohealthinvestor.com. 3 January 2007. Retrieved 4 November 2013.

External links[]

Retrieved from ""